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Abstract
Background: Activating transcription factor-2 (ATF2), a member of the leucine zipper family of DNA binding
proteins, has been implicated as a tumour suppressor in breast cancer. However, its exact role in breast cancer
endocrine resistance is still unclear. We have previously shown that silencing of ATF2 leads to a loss in the growth-
inhibitory effects of tamoxifen in the oestrogen receptor (ER)-positive, tamoxifen-sensitive MCF7 cell line and
highlighted that this multi-faceted transcription factor is key to the effects of tamoxifen in an endocrine sensitive
model. In this work, we explored further the in vitro role of ATF2 in defining the resistance to endocrine treatment.
Materials and methods: We knocked down ATF2 in TAMR, LCC2 and LCC9 tamoxifen-resistant breast cancer cell
lines as well as the parental tamoxifen sensitive MCF7 cell line and investigated the effects on growth, colony
formation and cell migration. We also performed a microarray gene expression profiling (Illumina Human HT12_v4)
to explore alterations in gene expression between MCF7 and TAMRs after ATF2 silencing and confirmed gene
expression changes by quantitative RT-PCR.
Results: By silencing ATF2, we observed a significant growth reduction of TAMR, LCC2 and LCC9 with no such
effect observed with the parental MCF7 cells. ATF2 silencing was also associated with a significant inhibition of
TAMR, LCC2 and LCC9 cell migration and colony formation. Interestingly, knockdown of ATF2 enhanced the levels
of ER and ER-regulated genes, TFF1, GREB1, NCOA3 and PGR, in TAMR cells both at RNA and protein levels.
Microarray gene expression identified a number of genes known to mediate tamoxifen resistance, to be
differentially regulated by ATF2 in TAMR in relation to the parental MCF7 cells. Moreover, differential pathway
analysis confirmed enhanced ER activity after ATF2 knockdown in TAMR cells.
(Continued on next page)
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: c.palmieri@liverpool.ac.uk
†Athina Giannoudis, Mohammed Imad Malki and Bharath Rudraraju
contributed equally to this work.
1Department of Molecular and Clinical Cancer Medicine, The Institute of
Systems, Molecular and Integrative Biology, University of Liverpool,
Sherrington Building, Ashton Street, Liverpool L69 3GE, UK
2The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK
Full list of author information is available at the end of the article
Giannoudis et al. Breast Cancer Research          (2020) 22:126 
https://doi.org/10.1186/s13058-020-01359-7
(Continued from previous page)
Conclusion: These data demonstrate that ATF2 silencing may overcome endocrine resistance and highlights
further the dual role of this transcription factor that can mediate endocrine sensitivity and resistance by modulating
ER expression and activity.
Keywords: ATF2, Tamoxifen, Endocrine resistance, Breast cancer
Introduction
Globally, breast cancer is a major cause of morbidity and
mortality. Oestrogen, which plays a key role in the growth
and differentiation of normal breast tissue, is also impli-
cated in the pathogenesis and progression of breast cancer
[1], with oestrogen receptor alpha (ERα) being expressed
in about 70% of breast cancers. Endocrine therapy [tam-
oxifen and/or aromatase inhibitors (AI)] has been proven
very successful in the clinical setting. However, de novo or
acquired resistance to endocrine therapy is a major clinical
problem and limits its use [2, 3]. Several studies have iden-
tified potential mechanisms of resistance to endocrine
therapies such as enhanced growth factor signalling,
changes in the expression and/or action of the ER, altered
expression of ER co-regulators, micro-RNA or long non-
coding RNA interference and DNA methylation [3–7]. In
addition, mutations of the ESR1 gene, encoding the ERα,
have been increasingly recognised as an important mech-
anism of endocrine therapy resistance, mainly to AIs, with
a prevalence of around 25% [8, 9]. Transcriptomic profil-
ing of MCF7 tamoxifen-sensitive and its tamoxifen-
resistant variant revealed differential expression of genes
involved in cell cycle control, transcriptional/translational
machinery, ESR1 regulation, dysfunctional mitochondrial
and oxidative phosphorylation and altered metabolism,
whereas proteomic analysis of acquired tamoxifen resist-
ance demonstrated downregulated ER-signalling, activa-
tion of alternative survival pathways and enhanced cell
motility and migration through regulation of the actin
cytoskeleton [3, 4, 10–12]. The adaptation of the tumour
cell from oestrogen to androgen dependent has been re-
cently demonstrated as another mechanism of resistance
to ER-targeted therapies [13]. Understanding the under-
lying molecular mechanisms that mediate resistance is re-
quired to improve the management of endocrine-
unresponsive breast cancer, and the development of novel
therapeutic strategies in the management of breast cancer.
Activating transcription factor-2 (ATF2), a member of
the leucine zipper family of DNA binding proteins, regu-
lates the transcription of various genes, including those in-
volved in apoptosis, cell growth, proliferation, inflammation
and DNA damage response [14, 15]. Dependent on its
binding partner, ATF2 binds to CRE (cAMP response
element) consensus sequences (5-TGACGTCA-3) or to
AP-1 (activator protein 1) consensus sequences (5-TGAC
TCA-3) [14]. ATF2 also possesses an intrinsic histone
acetyltransferase activity triggering its own DNA binding
effectiveness [16]. However, the exact role of ATF2 in
breast cancer is still unclear. ATF2 has been found to in-
crease the transcription of matrix metalloproteinase 13
(MMP13), which may help facilitate breast cancer bone
metastasis [17, 18]. In addition, cJun-ATF2 dimers have
been shown to lead to the transcription of cyclin A, which
increases cell proliferation [19], providing further evidence
for a possible oncogenic role for ATF2. Co-culture with
malignant epithelial cells in primary human adipose fibro-
blasts obtained from breast cancer patients increased the
levels of phosphorylated ATF2 (pATF2) at the promoter of
the aromatase gene responsible for oestrogen synthesis
[20]. Furthermore, pATF2 has been shown to facilitate the
transcription of MMP2, which increases migration in H-
Ras-transformed MCF10A human breast epithelial cells in-
dicating that ATF2 may play a role in breast cancer metas-
tasis [21]. ATF2 also forms a complex with c-Jun and c-Fos
that mediates HER2’s induction of cyclooxygenase-2
(COX2), involved in cancer development and metastasis
[22]. Several studies reported that v-src causes ATF2 and
CREB to bind the CRE/ATF site of the cyclin D1 gene,
leading to transcription of cyclin D1 in MCF7 human
breast cancer cells [23, 24]. Together, these findings are
strongly supportive of a role for ATF2 as an oncogene in
breast cancer.
In our previous study, we observed that pATF2 predicts
improved disease-free and overall survival in ER-positive
breast cancer patients treated with tamoxifen [25]. We
also showed that silencing of ATF2 led to a loss in the
growth-inhibitory effects of tamoxifen in the ER-positive,
tamoxifen-sensitive MCF7 cell line and that tamoxifen
treatment caused a dose-dependent phosphorylation of
ATF2 within its activation domain, enhancing its tran-
scriptional activity. That work suggested a tumour-
suppressive role of ATF2 in ER-positive breast cancer
[25]. The apparent dual function of ATF2 has been also
observed in skin tumourigenesis, where ATF2 has both
oncogenic and tumour-suppressive activities [15, 26, 27].
In the current study, we sought to investigate the in vitro
role of ATF2 in acquired resistance to endocrine therapy.
Materials and methods
Breast cancer cell lines
MCF7 cells obtained from the Cancer Research UK Cell
Services (Clare Hall Laboratories, South Mimms, Herts,
Giannoudis et al. Breast Cancer Research          (2020) 22:126 Page 2 of 17
UK) were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% foetal bovine
serum (FBS), 5 mM L-glutamine and 1% penicillin/
streptomycin (P/S). TAMR cells (MCF7-derived
tamoxifen-resistant cell line), a kind gift from Professor
RI Nicholson [28] were maintained in DMEM phenol
red-free supplemented with 5% charcoal/dextran-
stripped FBS (CSS), 1% P/S and 100 nM 4-
hydroxytamoxifen (4-OH-Tam) (all the reagents and
media were from Sigma-Aldrich Company Ltd., Gilling-
ham, UK). LCC2 (E2-independent, tamoxifen-resistant
and ICI 182,780-sensitive subline of the MCF7) and
LCC9 (ICI 182,780-resistant MCF7 variant and cross-
resistant to tamoxifen) were kind gifts from Professor R.
Clarke [29, 30]. LCC2 and LCC9 were cultured similarly
to TAMR cells but without tamoxifen.
ATF2-siRNA transfections, qRT-PCR and immunoblotting
Two small interfering RNA (siRNA) duplexes for ATF2
mRNA depletion (S3492 and S3493) and the non-
targeting siRNA (NT-siControl) (Silencer® Negative
Control: AM4635) were used in our experiments (Ther-
mofisher Scientific, Paisley, UK). Cells (2.5 × 105 cells/
well in 6-well plate) were transfected with 100 nM of
each of the ATF2-siRNA duplexes including the NT-
siControl using RNAiMAX, according to the manufac-
turer’s instructions (Thermofisher Scientific, Paisley,
UK) and incubated in DMEM phenol red-free medium
with 5% CSS. Following overnight incubation, the trans-
fected cells were changed to their standard growth
medium for 48 h. RNA was prepared using the Qiagen
RNeasy kit (Crawley, UK) and converted to cDNA with
the High-Capacity cDNA reverse transcription kit,
followed by quantitative real-time PCR (qRT-PCR) using
the TaqMan Gene Expression Assays, listed in supple-
mentary Materials and Methods, Table 1 (all from Ther-
mofisher Scientific, Paisley, UK).
Protein extracts and immunoblotting was performed
as previously described [25]. Briefly, following ATF2
knockdown, cell lysates were prepared in RIPA buffer
(Sigma-Aldrich Company Ltd., Gillingham, UK) supple-
mented with protease/phosphatase inhibitors (Roche
Diagnostics, Burgess Hill, UK). Proteins were separated
in 12% SDS-PAGE and probed with primary antibodies
at 4 °C overnight. Following secondary horseradish
peroxidase-conjugated antibody incubation (Dako UK
Ltd., Cambridgeshire, UK), membranes were developed
with Super-signal West Pico Chemiluminescent Sub-
strate (VWR International Ltd., Lutterworth, UK). The
antibodies were ATF2, p-ATF2, TFF1, ERα, GREB1,
PGR, NCOA3, HER2, ERK1/2 and pERK1/2 (Cell signal-
ling, Danvers, MA, USA) and β-actin (Insight Biotech-
nology, Middlesex, UK), and their details are listed in
supplementary Material and Methods, Table 2.
Cell growth assay
The SulfoRhodamine B (SRB) cell proliferation assay was
used for cell growth determination (GeneCopoeia, MD,
USA). For ATF2-siRNA and siControl transfections,
10 μl of siRNA-Lipofectamine complexes were added per
3 × 103 cells/well in a 96-well plate with 150 μl of
DMEM phenol red-free medium and 5% CSS. Standard
growth medium, with/without ligands, was added to the
plates the following day. SRB was performed according
to the manufacturer’s protocol and absorbance was mea-
sured using a Tecan Infinite M200 (TECAN UK Ltd.,
Reading, UK) plate reader at 492 nm. Results are
expressed as the mean ± standard deviation (SD) of trip-
licate wells from three independent experiments.
Soft agar colony formation assay
Soft agar gel-I (1% SA-I) was made from 2% low melting
temperature agarose (LMA) (Sigma-Aldrich Company
Ltd., Gillingham, UK) mixed with an equal amount of
standard medium for siRNA-transfected cells, while soft
agar gel-II (1% SA-II) was made from 2% LMA mixed
with equal amount of DMEM phenol-red free and 5%
CSS with 100 nM tamoxifen for siRNA-transfected cells.
SA-I and SA-II were plated at 2 ml/well in a 6-well plate
and placed at 4 °C to solidify (basement gel layer). Cells
were harvested separately, adjusted with SA-I or SA-II
to 1 × 104 cells/ml, plated on top of the pre-set basement
gel layer and placed at 4 °C for 10 min. Once set, the
cells were incubated at 37 °C in a humidified atmosphere
(5% CO2) for 28 days. After 28 days, cells were fixed and
stained with 5% MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide (Sigma-Aldrich Company
Ltd., Gillingham, UK), for 4 h and counted using an
Optronix Gel Count (Oxford Optronix, Oxford, UK).
The number of colonies for siControl, ATF2-siRNA1
and ATF2-siRNA2 transfected cells was calculated rela-
tive to the un-transfected (vehicle) control. Results are
expressed as the mean ± SD of triplicate wells from three
independent experiments.
Invasion and scratch-wound assay
To test the invasive and migratory ability of ATF2-
silenced cells, ATF2 knockdown was performed as previ-
ously described. The invasion assay was performed in
Transwell® plates with polycarbonate membrane inserts
pre-coated with Matrigel™ (BD Biosciences, Oxford, UK).
The cells were seeded onto the upper compartment
filled with 100 μl standard culture medium with 2% (v/v)
FBS. The lower compartment was filled with 500 μl
medium with 10% (v/v) FBS. The invasive cells that
crossed the membrane in a 24-h period were fixed,
stained with a 1% Crystal Violet Reagent (Sigma-Aldrich
Company Ltd., Gillingham, UK). Cell counting was cal-
culated by light microscope for siControl, ATF2-siRNA1
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and ATF2-siRNA2 transfected cells and was calculated
relative to the un-transfected (vehicle) control. Results
are expressed as the mean ± SD of triplicate wells from
three independent experiments.
ATF2-silenced cells were also seeded in 6-well plates
at a density of 2.5 × 105 cells/well and an artificial gap
was created with a yellow pipette tip. The cells were
rinsed several times with the appropriate medium to re-
move dislodged cells and images of living cells were cap-
tured at the indicated time points of 0, 12 and 24 h at a
magnification of × 4 using an inverted microscope
(Nikon Eclipse TE 2000-U). Images were analysed by
ImageJ 1.48v software (National Institute of Health,
USA) averaging the position of the migrating cells at the
wound edges. Results are expressed as the mean ± SD of
triplicate wells.
Gene expression microarray analysis
Microarray analysis was performed to identify genes that
were differentially regulated by ATF2 in TAMR cells
when compared to the tamoxifen-sensitive MCF7. ATF2
knockdown and RNA extraction were performed as de-
scribed above. Four biological replicates were prepared
for each experimental condition. Gene expression ana-
lysis was carried out on Illumina Human HT12 version
4 arrays and deposited to Gene Expression Omnibus
(GEO) repository (GSE145548). All data analyses were
performed on R using Bioconductor packages [31]. Raw
intensity data from the array scanner was processed
using the BASH and HULK algorithms as implemented
in the bead array package [31]. Log2 transformation and
quantile normalisation of the data was performed across
all sample groups. Differential expression analysis was
performed using the limma package [32]. Differentially
expressed genes were selected using a p value cut-off of
< 0.05 after application of false discovery rate (FDR) cor-
rection for multiple testing applied globally to correct
for multiple contrasts. Differentially expressed genes
were analysed by the ‘transcription factor network’ pre-
diction tool EnrichR [33] to identify top driver transcrip-
tion factors and pathway analysis (KEGG and REAC
TOME) was performed using the publically available
STRING (Functional protein association networks) data-
base v11 (string-db.org).
DNA methylation
ATF2 knockdown was performed as described and
DNA/RNA was extracted using the DNeasy/RNeasy kits
(Qiagen, Crawley, UK), respectively. Total RNA was re-
verse transcribed using the Quantitect RT kit (Qiagen,
Crawley, UK). Pyrosequencing primers were designed
using Pyromark Assay Design 2.0 software (Qiagen,
Crawley, UK) to measure the DNA methylation levels of
ESR1 and PGR after ATF2 knockdown and synthesised
by Eurofins MWG Operon (Ebersberg, Germany). The
primer sequences are listed in Supplementary Material
and Methods, Table 3. Genomic DNA was treated with
sodium bisulphite using the EZ DNA methylation Kit
(Zymo Research, CA, USA). PCR amplifications were
performed in a final volume of 25 μl using HotStarTaq
Master Mix (Qiagen, Crawley, UK), 200 nM biotinylated
primer, 400 nM non-biotinylated primer and 60 ng of
bisulfite-treated genomic DNA. The thermal profile was
95 °C for 5 min followed by 40 cycles of denaturation at
94 °C for 30 s, annealing at 51–56 °C for 30 s and exten-
sion at 72 °C for 30 s. The PyroMark Gold Q96 SQA Re-
agents and the PyroMark Q96 ID instrument (Qiagen,
Crawley, UK) were used for pyrosequencing analysis fol-
lowing the supplier’s protocol. The methylation index
for each promoter was calculated as the mean value of
mC/(mC + C), where C is unmethylated cytosine and
mC is 50′ methyl-cytosine, for all examined CpGs in the
target sequence.
Statistical methods
Student’s t test (two-sided) was used to compare any dif-
ferences observed between each experimental group and
the control group. All the t tests and the 95% CI (confi-
dence interval) were calculated by GraphPad Prism 5. A
p value less than 0.05 was considered significant.
Results
Knockdown of ATF2 by siRNA interferences has
differential effect on the growth and proliferation of
tamoxifen-sensitive MCF7 and resistant TAMR cell lines
The expression of ATF2 was initially assessed in parental
MCF7 cells and its tamoxifen-resistant subline TAMR.
There were no significant differences observed at the
protein and RNA expression levels between MCF7 and
TAMR cells (Supplementary Fig. 1A,B). However, as
previously reported, TAMR cells did exhibit increased
HER-2 protein levels when compared to MCF7 cells and
enhanced ERK1/2 activity (increased pERK1/2, Supple-
mentary Fig. 1A) [28]. In addition, while in MCF7 cells,
tamoxifen inhibited E2-induced growth (Supplementary
Fig. 1C), TAMR cells grew both in the absence of E2
(vehicle) and in the presence of tamoxifen (Supplemen-
tary Fig. 1D) confirming that TAMR cells were both
oestrogen-independent and tamoxifen-resistant. More-
over, there was no difference observed in the phosphor-
ylation status of ATF2 in vitro between MCF7 and
TAMR cells before or after siATF2 (Supplementary
Fig. 1E).
Loss of ATF2 in both the cell lines by siRNA was con-
firmed by immunoblotting (Fig. 1a–c) and the growth of
cells was determined by the SRB assay (Fig. 1d–f). The
efficiency of transfection (densitometry analysis) is pre-
sented in Fig. 1c indicating a significant reduction in
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ATF2 after siRNA in both MCF7 and TAMR cells.
While in MCF7 cells there was no significant difference
in growth relative to untransfected cells or cells trans-
fected with control siRNA (siControl), knockdown of
ATF2 was associated with strong growth inhibition in
TAMR cells (Fig. 1f: p = 0.0037 ATF2-siRNA1 and p =
0.0041 ATF2-siRNA2, day 5). To further validate our ob-
servations in the ATF2 dependency of tamoxifen-
resistant breast cancer cells, ATF2 knockdown was per-
formed in the independently derived endocrine-resistant
MCF7 cells, LCC2 and LCC9 [29, 30] (Supplementary
Fig. 2a–f) and showed similar results to the TAMR cells;
ATF2 silencing significantly inhibited the growth of both
LCC2 and LCC9 cell lines.
Moreover, a hallmark of carcinogenesis is the ability of
transformed cells to grow independently of a solid sur-
face, known as anchorage-independent growth. To in-
vestigate the effect of ATF2 in anchorage-independent
growth of MCF7s and TAMRs, we performed the soft-
agar colony formation assay after siRNA-mediated
knockdown of ATF2. While ATF2 knockdown inhibited
colony formation in MCF7 cells (Fig. 1g), knockdown of
ATF2 was associated with a substantially greater reduc-
tion in colony formation in TAMR cells (p = 0.0016 for
siRNA1 and 0.0056 for siRNA2) relative to control
(Fig. 1h). To further validate this observation, ATF2
knockdown was performed in LCC2 and LCC9 (Supple-










































Fig. 1 Effect of knockdown of ATF2 on growth and tumourigenesis of MCF7 and TAMR (MCF7-derived tamoxifen-resistant) cell lines. MCF7 (a) and TAMR
(b) cells were transfected with negative control siRNA (siControl), ATF2-siRNA1 and ATF2-siRNA2. Protein lysates were prepared and immunoblotting was
carried out for ATF2 with β-actin as a loading control. c Densitometry analysis of knockdown efficiency relative to untransfected cells. SRB growth assay for
MCF7 (d) and TAMR (e) indicated a significant growth reduction in TAMR cells after ATF2 silencing (n= 3). f Graph indicating the percentage of growth at
day 5 relative to untransfected cells. g The effect of ATF2 knockdown on tumourigenesis was determined by anchorage-independent colony formation.
Although there was a reduction of colonies in the MCF7 cells after ATF2 silencing, this reduction was more profound in the TAMRs (n= 3). Asterisks
indicate statistically significant (*p< 0.05, **p< 0.005) difference from untransfected cells
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obtained for TAMR cells. This indicated that although
ATF2 was important for anchorage-independent cell
growth in both MCF7 and TAMRs, the effect was more
profound on tamoxifen-resistant breast cancer cell lines,
suggesting that ATF2 targets and regulates additional
pathways associated with the tamoxifen resistance
phenotype.
Knockdown of ATF2 by siRNA alters the chemotactic and
migratory properties of the resistant TAMR cell lines
To investigate the role of ATF2 on invasion and migra-
tion of breast cancer cell lines, knockdown of ATF2 was
performed in both MCF7 and TAMR cells growing in
their standard growth media. The invasive and migratory
ability of MCF7 and TAMR cells after ATF2 knockdown
was determined by chemotaxis (Fig. 2a–d) and wound
healing scratch assays (Fig. 2e–h). While in MCF7 cells
there was no significant difference in cell migration rela-
tive to vehicle control (Fig. 3a, c), knockdown of ATF2
was associated with a significant inhibition of migration
in TAMR cells (Fig. 3b, d: p = 0.0075 ATF2-siRNA1 and
p = 0.0025 ATF2-siRNA2). To further validate this ob-
servation, wound healing scratch assay was performed.
ImageJ software was used to measure the migration abil-
ity of both MCF7 (Fig. 2e, g) and TAMR (Fig. 2f, h) cells.
Knockdown of ATF2 significantly reduced the migratory
capacity of the invasive TAMR cells (p = 0.0010 ATF2-
siRNA1 and p = 0.0015 ATF2-siRNA2 at 12 h and p <
0.0001 with both ATF2-siRNA1 and ATF2-siRNA2 at
24 h), whereas no effect was observed in the less invasive
MCF7 cells. Similar impairment in cell invasion and mi-
gration was obtained in LCC2 and LCC9 cell lines after
ATF2 silencing (Supplementary Fig. 3A-F). This indi-
cates that ATF2 plays an important role in regulating
migration of tamoxifen-resistant breast cancer cells,
compared to endocrine-sensitive MCF7 cells.
Differential gene expression analysis in MCF7 versus
TAMR cell lines revealed a shift from the ER-enriched
transcription factor network towards an ATF2-enriched
To identify the underlying mechanisms by which ATF2
regulates the growth and migratory ability of TAMR
cells, global gene expression analysis (microarray profil-
ing using Illumina Human HT12 v4 arrays) was carried
out both in MCF7 and TAMR before and after ATF2
knockdown including NT-siRNA as control. Differential
expression analysis was carried out using limma to iden-
tify, firstly, genes that were differentially expressed in
MCF7 and TAMR and, secondly, genes that were differ-
entially regulated by ATF2 in TAMR relative to MCF7.
Initial gene expression analysis between MCF7 and
TAMR cells identified 3260 genes that were significantly
upregulated (FDR < 0.05) and 4423 genes that were sig-
nificantly downregulated (FDR < 0.05) (Fig. 3a) in MCF7
cells relative to TAMR (full list of genes and pathway
enrichment analysis is provided in Supplementary file 1).
Functional protein association analysis using the STRI
NG database showed that MCF7 cells are enriched for
genes involved in oestrogen and nuclear receptor signal-
ling, cell cycle, lysosomal pathway and endocytosis. The
lysosomal degradation pathway regulates a variety of cel-
lular functions such as autophagy, endocytosis and
phagocytosis to maintain cellular homeostasis, and lyso-
somes are also involved in the regulation of ERα signal-
ling pathways that mediate physiological hormone-
induced effects [34]. On the other hand, TAMR cells are
enriched for genes involved in metabolic pathways
(mitochondrial metabolism, ATP production, fatty acid
metabolism and RNA processing) as previously observed
[10, 11, 35].
Transcription factor network enrichment analysis
(EnrichR) indicated an ESR1 and ER-regulatory gene en-
richment in MCF7 cells that were diminished in TAMR
(Fig. 3b, c with progesterone and oestrogen signalling
adjusted p = 0.017). A shift to an ATF2-enriched net-
work and TGF-β signalling pathway was observed in
TAMR cells (Fig. 3b, c with TGF-β signalling adjusted
p = 0.025) suggesting the importance of alternative
hormone-independent growth mechanisms.
Differential gene expression analysis after ATF2 silencing
revealed ER-responsive genes and pathways regulated by
ATF2 in tamoxifen resistance
To identify genes regulated by ATF2, we performed dif-
ferential gene expression analysis in MCF7 and TAMR
cell lines after knocking down ATF2 with two independ-
ent siRNAs (Fig. 4a, b). Differential analysis in MCF7
cells identified 373 genes up- and 287 downregulated
after ATF2 knockdown (Venn diagram Fig. 4c). In con-
trast, ATF2 knockdown in TAMR cells led to a substan-
tially greater number of genes differentially expressed
with 543 upregulated and 483 downregulated genes
(Venn diagram Fig. 4c) (full list of genes and pathway
enrichment analysis is provided in Supplementary file 2).
Focusing on differentially expressed genes specific to the
TAMR cell line (without changing in MCF7), we found
a reintroduction of ER and its signalling pathway upon
ATF2 knockdown along with a reduction in MYC tran-
scriptional activity by EnrichR (Fig. 4c). Similarly, func-
tional protein association analysis using the STRING
database on TAMR-upregulated genes after ATF2
knockdown showed an enrichment for adherent junc-
tions, drug metabolising enzymes, steroid hormone
biosynthesis, PTEN regulation, oestrogen and nuclear
receptor signalling. In addition, pathway enrichment
analysis on TAMR-downregulated genes after ATF2
knockdown showed enrichment for ribosomal path-
way (rRNA processing in the nucleolus and cytosol
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and RNA metabolism). Table 1 summarises the path-
ways that are differentially regulated in MCF7 versus
TAMR and in TAMR after ATF2 silencing. Since we
observed that MCF7 cells are enriched for genes in-
volved in oestrogen and nuclear receptor signalling in
comparison to the TAMRs and that these two path-
ways were upregulated in TAMRs after ATF2 silen-
cing, we focused to investigate further the effect of
ATF2 silencing in ER-regulated genes.
Firstly, to confirm the gene lists obtained from the
microarray data analysis, qRT-PCR was carried out using
specified TaqMan primers. A number of the ER-
regulatory key genes that were significantly up- or down-
regulated in TAMR after ATF2 knockdown presented
similar results by qRT-PCR (Fig. 5). To further evaluate
the effect of ATF2 knockdown on ER expression and ac-
tivity at both RNA and protein level, qRT-PCR and
western blotting were performed for the ESR1(ER) and
ER-regulated genes TFF1, PGR, GREB1 and NCOA3
(Fig. 6a–g). With the exception of PGR, TAMR cells had
a reduced expression of the ER-regulated genes TFF1,
GREB1 and NCOA3 compared to tamoxifen-sensitive
MCF7. Knockdown of ATF2 resulted in increased ex-
pression of ER and its targets TFF1, GREB1, NCOA3
and PGR in TAMR cells but not in MCF7 cells in both
the gene and protein levels. This indicated that knock-
down of ATF2 in TAMR cells enhances ER expression
and activity which confirmed our earlier results.
Moreover, the list of genes differentially expressed in
TAMRs after siATF2 was assessed by the Drug-Gene in-
teractions database (DGIdb) v3.1 (http://www.dgidb.org/
) and presented in supplementary file 3. Silencing of
ATF2 in TAMRs lead to downregulation of ABL1,
CDK4, CTGF, DNMT1, PARP3 and VEGFA that have
been linked to endocrine resistance and poor prognosis
in BC, and there are several drugs available targeting
these genes (FDA approved or in clinical trials, supple-
mentary file 3). In addition, silencing of ATF2 lead to
upregulation of genes such as PTEN and IGF1R.
DNA methylation analysis
DNA methylation levels of ESR1 and PGR were assessed
following ATF2 knockdown in parental MCF7 and tam-
oxifen resistance TAMR, LCC2 and LCC9. The threshold
for scoring hypermethylated samples was conservatively
set to 10% [36]. ESR1 and PGR promoters were unmethy-
lated in both parental and ATF2 knockdown derivatives.
In addition, global methylation in MCF7, TAMR, LCC2
and LCC9 in presence or absence of ATF2 was measured
by assessing long interspersed nucleotide element (LINE-
1) methylation [37]. Global methylation levels are shown
in detail in Supplementary Fig. 4A. Tamoxifen resistant
cells showed slightly increased global methylation com-
pared to parental MCF7 at the basal level. However, ATF2
knockdown did not result in any significant changes (p >
0.05 in all comparisons) in any of the cell lines tested. Rep-
resentative pyrograms of MCF7 and TAMRs are given in
supplementary Fig. 4B,C.
Discussion
The development of endocrine therapy resistance ap-
pears to involve multiple divergent mechanisms includ-
ing epigenetic changes affecting the expression of ER
and its target genes or deregulated ER-mediated gene
transcription [3–10]. Therefore, a better understanding
of the complexity of resistance will help us to identify
novel targets able to revert or abolish resistance to endo-
crine therapy. Studies utilising cell lines and patient-
derived xenografts models of acquired resistance have
indicated impaired ER-mediated transcriptional activity,
enrichment for genes involved in cell growth, cell sur-
vival and apoptosis and, more recently, activation of
oestrogen non-genomic signalling, involving mainly the
ERa/Src/PI3K complex [38–41]. Blocking the formation
of the ERa/Src/PI3K complex by a competitive peptide
partially restored tamoxifen sensitivity in the resistant
cells [41]. Moreover, blocking the AP1 transcription
complex (Jun, Fos, Maf and ATF2 protein subfamilies)
leads to increased tumour sensitivity to endocrine ther-
apy and delayed onset of resistance through the inhib-
ition of both proliferative and survival signals [40]. A
recent study highlighted that ATF2 promotes the devel-
opment and progression of urothelial cancer via cooper-
ation with androgen receptor and EGFR/ERBB2/ERK
pathway signalling and suggested that ATF2 inhibition
in association with AR inactivation may be a potential
effective therapeutic approach for urothelial cancer [42].
Although there is conflicting data regarding the prog-
nostic role of AR expression in endocrine treatment re-
sponse, an in vitro effect of AR expression on tamoxifen
resistance has been observed, potentially mediated
through activation of EGFR signalling pathways and the
adaptation of the tumour cells from oestrogen to andro-
gen dependent has been demonstrated as another
(See figure on previous page.)
Fig. 2 Effect of knockdown of ATF2 on migration of MCF7 and MCF7 derived tamoxifen-resistant cell line (TAMR). MCF7 (a, c, e, and g) and TAMR
(b, d, f, and h) cells transfected with negative control siRNA (siControl), ATF2-siRNA1 and ATF2-siRNA2. Chemotaxis assay (migration) was carried
out and migrated cells were counted relative to vehicle control (n = 3). ATF2 knockdown inhibited the migratory ability of TAMR (b, d) cells but
not of the MCF7 (a, c). Similarly, knockdown of ATF2 reduced the migratory ability of TAMR (f, h) cells in an in vitro wound healing scratch assay
but did not affect the MCF7 (e, g) cells. Asterisks indicate statistically significant (*p < 0.05, **p < 0.005) difference from vehicle control
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mechanism of resistance to ER targeted therapies [13,
43, 44]. Therefore, silencing ATF2 may be beneficial to
endocrine therapy resistance.
In a previous study from our group, we showed that
ATF2 silencing leads to a loss in the growth-inhibitory
effects of tamoxifen in the ER-positive, tamoxifen-
sensitive MCF7 cell line and that tamoxifen treatment
caused a dose-dependent phosphorylation of ATF2
within its activation domain, enhancing its transcrip-
tional activity, suggesting a tumour-suppressive role of
ATF2 in ER-positive breast cancer [25]. In the current
study, we demonstrated in vitro that the transcription
factor ATF2, part of the AP1 complex, represents a key
factor in acquired endocrine resistance by facilitating a
shift towards ER-independent transcription and silencing
of ATF2 leads to the reversal of this resistant phenotype.
Firstly, we demonstrated that knockdown of ATF2 had
a differential effect on the growth and proliferation of
MCF7 and the endocrine-resistant cell lines TAMR,
LCC2 and LCC9. Interestingly, transient knockdown of
ATF2 significantly inhibited the growth of TAMR, LCC2
and LCC9 but had little effect on the growth of MCF7
cells. In addition, ATF2 silencing was also associated
with a significant reduction in colony formation in the
endocrine-resistant cell lines in comparison to the
MCF7-sensitive cells. These results indicate that ATF2
plays an important role in regulating growth of
tamoxifen-resistant breast cancer cell lines, without af-
fecting the growth of the tamoxifen-sensitive cells, by al-
tering signalling pathways that lead to reduced cell
proliferation and/or increased apoptosis and by affecting
their anchorage-independent growth and tumorigenic
potential. The effect of siATF2 in the induction of apop-
tosis in MCF7 and TAMR cells is presented in supple-
mentary Fig. 5 whereas the lack of difference in the
phosphorylation status of ATF2 in vitro between MCF7
and TAMR cells before or after siATF2 (supplementary
Fig. 1E) highlights further the effect of ATF2 as a tran-
scription factor and not due to its activity. We previously
showed that high expression of p-ATF2 (69/71) was as-
sociated with longer disease-free (DSS) and breast
cancer-specific survival (BCSS) in ER-positive high-risk
patients exposed to tamoxifen [25]. However, these pa-
tients do not represent a tamoxifen-resistant model to
compare it to the current in vitro work. Our data is
similar to a number of studies mainly in melanoma, pan-
creatic and oesophageal cancer where inhibition or
silencing of ATF2 leads to an induction of apoptosis and
inhibition of tumour growth and metastasis [45–48].
We further showed that silencing ATF2 alters the
chemotactic and migratory properties of the resistant
cell lines and reverts the migratory capacity of the inva-
sive TAMR, LCC2 and LCC9 cells with no effect in the
less invasive MCF7 cells. This highlights further the dis-
tinct transcriptional activities between the endocrine re-
sistant and sensitive cells and the importance of ATF2
in reverting the malignant phenotype and restoring sen-
sitivity to endocrine therapy.
The mechanisms by which ATF2 regulates the growth
and migratory ability of TAMR cells in comparison with
MCF7 was evaluated by microarray gene expression ana-
lysis of both cell lines before and after ATF2 silencing.
Following ATF2 silencing, analysis was carried out to
identify genes that were differentially expressed in
TAMR cells without changing in MCF7. This revealed a
number of ER-responsive genes and pathways regulated
by ATF2 in tamoxifen resistance and highlighted a shift
from the ER-enriched towards an ATF2-enriched tran-
scription factor network. Although the endogenous
levels of ATF2 were not found to be significantly differ-
ent between the cell lines according to our microarray
data (reconfirmed by qRT-PCR and western blot), en-
hanced expression of ATF3 and ATF4 (members of the
ATF family) was observed in TAMRs, suggesting en-
hanced expression and activity of ATF transcription fac-
tors in tamoxifen resistance. Knockdown of ATF2 in
TAMR cells differentially inhibited the expression of
genes that are well documented in the literature to play
key roles in mediating tamoxifen resistance such as
VEGFA, ABL1, FOXM1 and DNMT1 [3, 7, 11, 12, 49,
50]. Moreover, ATF2 knockdown also inhibited the ex-
pression of CDK4 and ATF3 which were found to be
overexpressed in TAMR cells relative to MCF7. Many of
the genes differentially expressed in TAMRs cells after
ATF2 silencing (Supplementary file 3) are drug targets
and could be potentially used to overcome the
endocrine-resistant phenotype. For instance, inhibition
of ABL in ER-positive breast cancer resulted in
sensitization to anti-oestrogen therapies [49, 51, 52]
whereas CDK4/6 inhibitors have demonstrated clear
clinical efficacy in the treatment of ER-positive, HER2-
negative breast cancer when combined with endocrine
therapy [53, 54]. DNMT1 overexpression in TAMR cells
leads to aberrant methylation of the PTEN promoter
(See figure on previous page.)
Fig. 3 Differential gene expression analysis in basal MCF7 versus TAMR cell lines revealed an ATF2-enriched transcription factor network. a
Heatmap of genes that were differentially expressed in MCF7 (blue) relative to TAMR (red) cells at basal level. This analysis identified 3260
upregulated and 4423 downregulated genes in TAMR cells relative to MCF7. b Enrichment analysis identified a shift from the ER (ESR1)-enriched
transcription factor network present on MCF7 (blue) towards an ATF2-enriched transcription factor network on TAMR (red). c KEGG enrichment
also identified a shift from the oestrogen and progesterone pathways to TGF-β and metabolic pathways
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resulting into loss of PTEN expression and activation of
the PI3K/AKT pathway. Therefore, drugs targeting
DNMT1 (azacitidine, decitabine) may be of potential
clinical use [55, 56]. CTGF overexpression has been cor-
related to decreased survival and endocrine resistance in
ER-positive breast cancer patients and identified as a po-
tential therapeutic target to overcome resistance [57]
whereas ruxolitinib blocked the EMT process and VEGF
production through the JAK/STAT3 pathway, conse-
quently suppressing tamoxifen-resistant cell migration
and angiogenesis [58]. We also demonstrated IGF1R ex-
pression was upregulated after silencing ATF2. Of note,
a randomised study targeting IGF1R with ganitumab in
combination with endocrine therapy for hormone-
receptor positive locally advanced or metastatic breast
cancer demonstrated a significantly worse overall sur-
vival in those women receiving ganitumab as compared
to placebo [59]. Previously, it had been reported that
IGF1R is reduced in tumour biopsy at the time of recur-
rence or resistance to tamoxifen and time to progression
was significantly increased for IGF1R rich patients [60].
These observations alongside ours would support a role
for agonising IGF1R in ER-positive breast cancer.
Knockdown of ATF2 also resulted in increased expres-
sion of ESR1 and ER-target genes, including TFF1,
GREB1, NCOA3 and PGR in TAMR cells but not in
MCF7 cells. This was also reconfirmed in the protein
levels indicating that knockdown of ATF2 in TAMR
cells enhances ER-regulated gene expression and activity.
Using the Kaplan-Meier Plotter (https://kmplot.com/
analysis/) [61] for breast cancer we observed that mRNA
expression of NCOA3, GREB1 but not ATF2 and TFF1
correlated with progression-free survival (PFS) whereas
NCOA3, GREB1 and TFF1 correlated with overall sur-
vival (OS) in ER-positive breast cancer patients
systemically-treated with tamoxifen only (Supplementary
Fig. 6). The KM plotter data for ATF2 is in agreement
with our previous work utilising clinical samples [25].
However, it cannot distinguish between tamoxifen-
sensitive and tamoxifen-resistant patients. In the current
study, we did not examine any clinical samples as out
work was purely in vitro models of endocrine resistance.
(See figure on previous page.)
Fig. 4 Differential gene expression analysis after ATF2 silencing revealed ER-responsive genes and pathways regulated by ATF2 in TAMR.
Heatmaps of genes that were a upregulated and b downregulated in TAMRs (red) cells after ATF2 silencing relative to MCF7 (blue). c Enrichment
analysis revealed ATF2 silencing in TAMR cells leads to the reintroduction of the ER signalling network and a reduction in MYC. Venn diagrams of
differentially regulated genes in TAMRs after ATF2 silencing. A total of 543 upregulated (d) and 483 downregulated (e) genes were commonly
identified after both ATF2-siRNA knockdown (si1 and si2 vs siNT)
Table 1 Pathways that are differentially regulated in MCF7 versus TAMR and in TAMR after ATF2 silencing. Commonly identified
pathways dysregulated between MCF7 and TAMRs and re-instated after ATF2 knockdown. The complete list of KEGG and REAC
TOME pathways are presented in Supplementary files 1 (MCF7 vs TAMR) and 2 (TAMRs after siATF2 knockout)
Number term ID Term description
Pathways upregulated in MCF7 (downregulated in TAMRs)
HSA-9018519 Oestrogen-dependent gene expression
HSA-9006931 Signalling by Nuclear Receptors
Pathways upregulated in TAMRs after siATF2
HSA-9018519 Oestrogen-dependent gene expression
HSA-9006931 Signalling by Nuclear Receptors
Pathways downregulated in MCF7 (upregulated in TAMRs)
hsa03010 Ribosome
HSA-8953854 Metabolism of RNA
HSA-6791226 Major pathway of rRNA processing in the nucleolus and cytosol
HSA-1799339 SRP-dependent cotranslational protein targeting to membrane
HSA-71291 Metabolism of amino acids and derivatives
Pathways downregulated in TAMRs after siATF2
hsa03010 Ribosome
HSA-8953854 Metabolism of RNA
HSA-6791226 Major pathway of rRNA processing in the nucleolus and cytosol
HSA-1799339 SRP-dependent cotranslational protein targeting to membrane
HSA-71291 Metabolism of amino acids and derivatives
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Pathway analysis of genes upregulated in TAMRs after
ATF2 silencing showed very strong enrichment for
adherens junction, oestrogen and nuclear receptor sig-
nalling and drug metabolism whereas similar analysis of
genes downregulated in TAMRs after ATF2 silencing
showed enrichment for the ribosome (Supplementary
files 1 and 2). The pathway analysis confirms our func-
tional studies of anchorage-independent cell growth and
migration and is in agreement with a previous study that
observed an increased activity of mitochondrial biogen-
esis and expression of ribosomal genes in the anchorage-
independent cell growth gene signature [62].
Finally, DNA methylation has been implicated in the
development of tamoxifen resistance [6, 7]. However, in
our study, although tamoxifen-resistant cells showed
slightly increased global methylation compared to paren-
tal MCF7 at basal level, ATF2 knockdown did not trig-
ger any significant changes indicating that ATF2 does
not affect the methylation profile of these cell lines.
Conclusion
Our work confirms previous studies showing that
tumour cells adapt to oestrogen deprivation during
treatment with tamoxifen and/or AIs by the activation of
alternate signalling pathways and that abrogation of al-
ternative growth factor signalling may restore sensitivity
to endocrine therapy. Moreover, as we previously
showed that ATF2 plays a tumour-suppressive role in
ER-positive endocrine sensitive breast cancer, the
current data on an in vitro endocrine-resistant model
highlights the dual role of ATF2 in breast cancer and
suggests that ATF2 targeting has the potential of being
effective novel therapeutic approach in endocrine-
resistant breast cancer. Therefore, based on the in vitro
data and pathway analysis presented in this study, we
propose the following model presented in Fig. 6h, i: In
endocrine-resistant cells, where the classical ER-
regulated model of gene transcription is not the domin-
ant route, targeting the ATF-2 transcription factor or its
Fig. 5 Validation of genes identified using microarray. MCF7 and TAMR cells were transfected with silencer negative control siRNA, ATF2 siRNA1
and ATF2 siRNA2. qRT-PCR was carried out using Taqman primers for the genes indicated. Data analysis for each cell line was carried out relative
to the siControl (n = 3) and asterisks indicate the genes that were significantly changed after ATF2 knockdown (*p < 0.05, **p < 0.005)














































Fig. 6 (See legend on next page.)
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key downstream signalling targets represents a new
mechanism to revert resistance and enhance sensitivity
to endocrine therapy. However, additional genes and
pathways affected by ATF2 may interfere and/or con-
tribute to this model and further in vivo work could en-
hance our knowledge into the mechanistic action of
ATF2.
Supplementary Information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13058-020-01359-7.
Additional file 1: Supplementary Table 1. Taqman assays used in the
study. Supplementary Table 2. Details of the antibodies used in the
study. Supplementary Table 3. The primer sequences used for DNA
methylation analysis.
Additional file 2: Supplementary Fig. 1. Validation of ATF2 expression
in MCF7 and TAMR cells and the effect of ATF2 knockdown. The protein
(A) and mRNA (B) expression of ATF2 was similar between MCF7 and
TAMR cell lines. However, (A) TAMRs also showed increased protein
expression of HER2 and enhanced ERK1/2 activity. SRB growth assay was
performed on MCF7 (C) and TAMR (D) cells treated with vehicle,
estradiol (E2) (10 nM), 4-hydroxytamoxifen (Tam) (100 nM) or both E2 and
Tam. Tamoxifen inhibited E2-induced growth of MCF7 cells whereas,
TAMR cells grew both in the absence of E2 and in the presence of tam-
oxifen confirming their estrogen-independent and tamoxifen-resistant
phenotype. Supplementary Fig. 2. Effect of ATF2 knockdown on
growth and tumourigenesis of MCF7 derived tamoxifen-resistant cell lines
LCC2 and LCC9. LCC2 (A) and LCC9 (B) cells were transfected with nega-
tive control siRNA (siControl), ATF2-siRNA1 and ATF2-siRNA2. Protein ly-
sates were prepared and immunoblotting was carried out for ATF2 with
β-actin as a loading control. SRB growth assay for LCC2 (C) and LCC9 (D)
indicated a significant growth reduction in both cell lines similar to TAMR
cells after ATF2 silencing (n = 3). (E) Graph indicating the % of growth at
day 5 relative to untransfected cells. (F) Densitometry analysis of knock-
down efficiency relative to untransfected cells. (G,H) The effect of ATF2
knockdown on tumourigenesis was determined by anchorage-
independent colony formation. There was a reduction of colonies in both
the LCC2 (G) and LCC9 (H) cells similar to the TAMRs (n = 3). Asterisks in-
dicate statistically significant difference from untransfected cells (*p <
0.05, **p < 0.005). Supplementary Fig. 3. Effect of ATF2 knockdown on
migration of MCF7 derived tamoxifen-resistant cell lines LCC2 and LCC9.
LCC2 (A,C,E) and LCC9 (B,D,F) cells were transfected with negative con-
trol siRNA (siControl), ATF2-siRNA1 and ATF2-siRNA2. Chemotaxis assay
(migration) was carried out and migrated cells were counted relative to
vehicle control (n = 3). ATF2 knockdown inhibited the migratory ability of
both the LCC2 (A,C) and LCC9 (B,D) cells. Similarly, knockdown of ATF2
reduced their migratory ability (E: LCC2 and F: LCC9) in an in vitro wound
healing scratch assay with the maximum effect observed at 24 hours. All
the experiments were performed in triplicates. Asterisks indicate
statistically significant difference from vehicle control (*p < 0.05, **p <
0.005). Supplementary Fig. 4. DNA Methylation Analysis. (A) Long inter-
spersed nucleotide element (LINE-1) methylation status. Data are pre-
sented as percent. (B) Representative pyrograms from the DNA
methylation analysis of ESR1 in MCF7 in presence or absence of ATF2 are
shown. X axis shows the dispensation order; the examined sequence is
shown at the top of each pyrogram. Gray lanes are indicative of individ-
ual CG dinucleotides; yellow lanes indicate the bisulfite conversion con-
trols. (C) Representative pyrograms from the LINE-1 methylation of MCF7
in presence or absence of ATF2 are shown. X axis shows the dispensation
order; the examined sequence is shown at the top of each pyrogram.
Gray lanes are indicative of individual CG dinucleotides; yellow lanes indi-
cate the bisulfite conversion controls. Supplementary Fig. 5. Effect of
ATF2 knockdown on apoptosis of MCF7 and TAMR cells. MCF7 and TAMR
cells untreated and treated with siControl and siATF2 were stained with
the FITC labelled-Annexin V and propidium iodide (PI) Staining Solution
and analyse by FACS. Live cells (L) are FITC-Annexin V−/PI-, early apop-
totic cells (A) are FITC-Annexin V+/PI-, whereas late apoptotic cells/nec-
rotic cells (N) are FITC-Annexin V+/PI+ and dead cells (D) are FITC-
Annexin V−/PI+. We observed that there was no induction of apoptosis
in MCF7 cells (no difference between untreated, siControl and siATF2)
but in TAMR cells there was a shift in A (early apoptosis) and N (late
apoptosis/necrosis) from 7.70% and 1.52% respectively in the untreated
cells to 11.57 and 3.94% after siControl and 17.49% and 18.81% after
siATF2 (ATF2 silencing). Supplementary Fig. 6. Kaplan-Meier Plot ana-
lysis for expression of TFF1, GREB1 or NCOA3, to determine correlation
with progression free or overall survival in ER+ patients. Using the
Kaplan-Meier Plotter (https://kmplot.com/analysis/) for ER-positive breast
cancer patients systemically-treated with tamoxifen only we observed
that (1) for progression free survival (PFS), mRNA expression of NCOA3
(B), GREB1 (D) but not ATF2/CREB2 (A) and TFF1/BCEI (C) correlated with
PFS and (2) for overall survival (OS), mRNA expression of NCOA3 (B),
TFF1/BCEI (C) and GREB1 (D) but not ATF2/CREB2 (A) correlated with OS.
Additional file 3: Supplementary file 1. MvsT_DE Genes and Pathway
analysis.
Additional file 4: Supplementary file 2. siATF2 MvsT_DE Genes and
Pathway analysis.
Additional file 5: Supplementary file 3. Drug targets after siATF2 in
TAMR.
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Fig. 6 Effect of knockdown of ATF2 on ER and ER-regulated genes and proposed model of resistance. a–f MCF7 (left bars) and TAMR (right bars)
cells were transfected with ATF2 siRNA and qRT-PCR was carried for ATF2 (a), ERα (ESR1) (b), TFF1 (c), GREB1 (d), PGR (e) and NCOA3 (f) using
TaqMan primers. GAPDH was used as the housekeeping gene and changes in mRNA levels after ATF2 knockdown were calculated relative to the
control. Asterisks indicate the genes that were significantly changed after ATF2 knockdown (*p < 0.05, **p < 0.005). g Protein lysates were also
prepared in triplicates of three independent experiments and immunoblotting was carried out using the antibodies indicated. ATF2 knockdown
had no effect on the ER and ER-regulated genes on the tamoxifen-sensitive MCF7 cells but affected their expression both on the mRNA and
protein levels on the tamoxifen-resistant TAMRs. The following model of resistance is proposed: h In endocrine-sensitive cells, gene transcription
is ER-dependent and endocrine therapy is able to stop their growth and proliferation. However, endocrine-resistant cells have a shift from ER-
dependent to an ER-independent ATF2-dependent transcriptional program and therefore, they are not responding to endocrine treatment. i
Targeting the ATF-2 transcription factor in endocrine-resistant cells represents a new mechanism to revert resistance and enhance endocrine
sensitivity. The genes shown in this model (h, i) such as TFF1, GREB1 and NCOA3 are examples of resistance candidates only, since their
biological function to endocrine resistance has not been validated in animal models in this study
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